WM patients and caregivers under the age of 50:Join the Young WM International Support Group on May 16th with special guest, Dr. Shayna Sarosiek!

Workshop Date and Time: Wednesday, May 25, 2022, 1:30 – 2:30 pm, Eastern Time. Registrants can listen in live over the phone or online as a webcast. Click below to learn more or register for this workshop.

In this issue of the IWMF Torch, Dr. Jorge Castillo reviews the disgnosis, indications to treat, and treatment options for Bing Neel Syndrome (BNS) in patients with WM, as these have a direct impact on further understanding the choices available to manage BNS.

Our IWMF Support Group Leaders and International Affiliates had the pleasure of meeting with Dr. Shayna Sarosiek of Dana-Farber Cancer Institute this week. Dr. Sarosiek covered many topics, including Evusheld, CAR-T therapy, and WM treatments on the horizon. This is a fabulous and timely presentation you don't want to miss!

When faced with a WM diagnosis, what determines the best treatment for YOU? In this 30-minute webinar, Dr. Jorge Castillo will review key factors that affect treatment decisions, emerging treatment research, and tips for partnering with your healthcare team.

Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies.

This program is designed to provide attendees with essential information that  will help you participate more actively and confidently in decisions about your  Waldenström Macroglobulinemia treatment and survivorship.

When a clinical trial showed the targeted drug ibrutinib to be highly effective in patients with a form of lymphoma called Waldenström macroglobulinemia, the results were so compelling that the U.S. Food and Drug Administration approved the drug for all patients with the disease, even though the trial included only patients previously treated with other agents.

The cover article for the first issue of The Torch for the new year is by Dr. Shayna Sarosiek, of the Bing Center for Waldenstrom's Macroglobulinemia, Dana-Farber Cancer Institute. She discusses amyloidosis, its diagnosis, symptoms, and treatments. While it’s a relatively rare complication of a rare disease, it is prudent for us to be aware of it.

Steven P. Treon, MD, MA, PhD, Professor of Medicine, Harvard Medical School, Boston, Massachusetts, discusses preliminary clinical data from a phase 1b study of mavorixafor in combination with ibrutinib for patients with Waldenström macroglobulinemia with MYDD88 and CXCR4 mutations. These data were presented at the 2021 American Society of Hematology (ASH) Annual Meeting.